Actively Recruiting
A Study of SHR-4375 in Subjects With Solid Tumors
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2025-01-22
208
Participants Needed
1
Research Sites
120 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is an open-label, three-part study to evaluate the safety and efficacy of SHR-4375 for injection in subjects with solid tumors.
CONDITIONS
Official Title
A Study of SHR-4375 in Subjects With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must voluntarily join the study and sign the informed consent form.
- Have measurable disease as defined by RECIST v1.1.
- Have an ECOG performance status of 0 or 1.
- Have a life expectancy of at least 12 weeks.
- Have advanced solid tumors confirmed by cytology or histology who have failed or are intolerant to standard therapy, have no standard therapy, or refuse standard therapy.
You will not qualify if you...
- Have symptomatic, untreated, or active central nervous system metastases.
- Have any active autoimmune disease or a history of autoimmune disease.
- Have active hepatitis B or hepatitis C.
- Have severe infections before starting study treatment.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China, 200032
Actively Recruiting
Research Team
Y
Yuanchao Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here